Alpha memo: resveratrol exercise signal

Research question: How far does the Receipt 1 signal transfer across the setting tested by Receipt 2?

One-sentence alpha: resveratrol / exercise does not carry one stable direction across the two receipts; the supported alpha is an endpoint- and setting-bounded comparison rather than a universal benefit or harm claim.

Receipt 1: Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats | 2012 | 10.1113/jphysiol.2012.230490

Receipt 2: Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men | 2014 | 10.1113/jphysiol.2013.270256

Synthesis: Receipt 1 reports Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats in an animal model. Receipt 2 reports Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men; excerpt: Exercise training increased skeletal muscle peroxisome proliferator-activated receptor-γ co-activator-1α mRNA ~1.5-fold, cytochrome c protein ~1.3-fold, cytochrome c oxidase I protein ~1.5-fold, citrate synthase activity ~1.3-fold, 3-hydrox in a human study. The comparison is bounded to resveratrol / exercise, and should not be read as advice, settled science, or a broad class claim. Bounded contrast: Receipt 1 axes: rats, strength, exercise, training, cardiac, performance, function. Receipt 2 axes: men, aged, human, endurance, exercise, training, metabolic, inflammatory. Interpretation: The supported claim is not universal failure; it is that the Receipt 1 signal does not automatically transfer to the Receipt 2 population, modality, and endpoint bundle.

Why this is surprising: The same named anchor is not enough. The useful signal is the boundary between the two receipt settings and endpoints, not a literature-average claim about resveratrol / exercise.

Limitations: This pair does not isolate whether species, population, dose, duration, modality, or endpoint class explains the split.

Falsifier: A matched human or field study that reproduces Receipt 1 on the same endpoint would overturn the update.

Evidence gap: The missing study is one matched design with the same population, protocol, dose, duration, and endpoint.

Next test: Run the same resveratrol / exercise comparison in one matched design before treating the signal as general.